AURA logo

Aura Biosciences, Inc.

AURA
Healthcare|Biotechnology|US
$6.56
+0.22 (+3.47%)
DCF Value
$0.67
Tangible Book / Share
$3.32
Cash / Share
$3.41
Next Earnings Report
Mar 30, 2027
EPS est. -$0.35
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Aug 11, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (6)

Nov 2026
Est. completion
P2Eye Cancer
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884n=24
Mar 2027
Est. completion
P1Non-muscle-invasive Bladder Cancer
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868n=55
Nov 2027
Est. completion
P3Choroidal Melanoma
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690n=108
Jul 2028
Est. completion
NAObesity & Overweight
High-Intensity Interval Training in Low Versus Normal Oxygen: Effects on Body Fat and Gut Health in Adults Aged 50-75 With Overweight or Obesity (HYPOXFAT)
NCT07796971n=32
Aug 2028
Est. completion
Choroidal Melanoma
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
NCT07421739n=15
Dec 2028
Est. completion
Choroidal Melanoma
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379n=63

Recent Press Releases

Aura Biosciences to Participate in Upcoming Investor Conference
Nov 3, 2026 · GlobeNewsWire
Aura Biosciences to Participate in Upcoming Investor Conference
Sep 2, 2026 · GlobeNewsWire
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2026 · GlobeNewsWire

SEC Filings (71)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 1, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 1, 2026S-8Employee stock planDocumentIndex
Aug 20, 2026EFFECTDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 2026S-3Shelf registrationDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 8, 20268-KMaterial eventDocumentIndex
Jun 29, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jun 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
May 19, 2026S-8Employee stock planDocumentIndex
May 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
May 5, 2026424B5Offering prospectusDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
May 4, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 4, 2026S-3MEFShelf registrationDocumentIndex
May 4, 2026424B5Offering prospectusDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 20, 2026ARSAnnual report to holdersDocumentIndex
Apr 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 30, 2026S-8Employee stock planDocumentIndex
Mar 30, 202610-KAnnual reportDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Oct 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex